Cowen & Co
http://www.cowen.com/default.htmlCowen and Company offers investment banking services, including equity research, equity and convertible debt financings, mergers and acquisitions advisory services, and restricted security sales.
TD Cowen Reiterates Buy Rating on Protara Therapeutics (TARA): "encouraged by Q4 operational update"
-
Protara prices $75 million stock offering at $5.75 per share
-
Protara Announces Pricing of $75 Million Public Offering
-
Protara Therapeutics launches $75 million public stock offering
-
Protara Announces Proposed Public Offering
-
Protara Therapeutics to Participate in Upcoming Investor Conferences
-
Protara Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference
-
Protara Announces Closing of $100 Million Public Offering
-
Protara Announces Pricing of $100 Million Public Offering
-
Protara Therapeutics (TARA) Announces Proposed Public Offering
-
Protara Announces Proposed Public Offering
-
TD Cowen Reiterates Buy Rating on Protera Therapeutics (TARA)
-
TD Cowen Reiterates Buy Rating on Protera Therapeutics (TARA)
-
TD Cowen Reiterates Buy Rating on Protera Therapeutics (TARA)
-
Protara Therapeutics to Present at the TD Cowen 5th Annual Oncology Innovation Summit
-
TD Cowen Reiterates Buy Rating on Protera Therapeutics (TARA)
-
Protara Therapeutics to Present at the TD Cowen 44th Annual Health Care Conference
-
Protara Therapeutics to Participate in Upcoming Investor Conferences
-
Protara Therapeutics to Participate in Upcoming Investor Conferences
-
Pre-Open Stock Movers 10/12: (RRD) (TARA) (QTRX) Higher; (CVAC) (RLAY) (TREX) Lower (more...)
-
Protara Therapeutics Announces Pricing of $147.6 Million of Securities in Concurrent Public Offerings of Common Stock and Preferred Stock
-
ArTara Therapeutics Inc. (TARA) Announces Proposed Concurrent Public Offerings of Common Stock and Preferred Stock
-
Protara Therapeutics Announces Proposed Concurrent Public Offerings of Common Stock and Preferred Stock

